Cure My Disease

Don't miss your cure!

 Log in / Sign up

New semaglutide injection tested against wegovy for obesity

NCT ID NCT06738979

Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are testing a semaglutide injection called TQF3510 against Wegovy, a similar drug, in adults with obesity. The trial enrolls 408 people aged 18 to 70 with a body mass index of at least 28 who have tried dieting without success. Participants receive one of the two injections for 44 weeks, and researchers measure weight loss and waist circumference to see if the new injection works as well as Wegovy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide injection
What this could lead to
If it works, this could offer another semaglutide option for weight management, potentially increasing access and competition.
What could go wrong
The trial may show the new injection is not equivalent to Wegovy, or differences in side effects could emerge. Results may not apply to everyone with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

408 people

The number who actually took part.

Started

Mar 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years old, gender is not limited; * Body mass index (BMI) ≥ 28 kg/m2; * Self-report at least one unsuccessful diet and weight loss history; * Patients must give informed consent to this study before the trial and sign the informed consent voluntarily. Exclusion Criteria: * Pregnant or lactating women or men or women of childbearing age who had a pregnancy plan during the study period (including a spouse), or who refused to take the contraceptive measures specified in the programme during the study period; * Have a history of diabetes of any type; * Patients who had used any hypoglycemic drugs within 90 days before screening; * Personal or first-degree relatives have a personal or family history of thyroid C-cell tumor or multiple endocrine tumor syndrome type 2; * Use of any drugs for weight management within 90 days prior to screening; * Previous or planned weight loss related treatment through surgery or other weight loss means during the study period; * Have a history of major depression or serious mental illness; * Mental Health Scale (PHQ-9) score ≥ 15 during screening; * History of acute pancreatitis within 180 days prior to screening; * Have a history of chronic pancreatitis or pancreatic surgery; * Laboratory tests during screening meet any of the following criteria: 1. Alanine aminotransferase (ALT)\> 2.5× upper limit of normal (ULN), aspartate aminotransferase (AST)\>2.5 ULN; 2. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2; 3. calcitonin ≥ 50 ng/L (pg/mL); 4. Triglyceride (TG) ≥500 mg/dl (5.7mmol/L); 5. Thyroid stimulating hormone (TSH) \>6 mIU/L or \<0.4 mIU/L. * When virological tests at the time of screening show any of the following: 1. Hepatitis C virus (HCV) antibody positive, and HCV virus titer detection value exceeds the upper limit of normal value; 2. HBsAg positive and Hepatitis B virus (HBV) DNA test value exceeds the upper limit of normal value; 3. HIV positive; 4. Active syphilis: the screening period of treponema pallidum antibody positive and non-Treponema pallidum serum test (RPR or TRUST) positive; * Uncontrolled or poorly treated hypertension; * Clinically significant cardiovascular and cerebrovascular disease in the 6 months prior to screening; * People who are allergic to Semaglutide injection or any component of Wegovy®, or to other GLP-1 receptor agonists, or who have a pre-existing allergic disorder; * Participated in any other clinical trial within 3 months prior to screening; * The subject is unable to comply with the treatment plan and diet and exercise plan established by the investigator; * There are secondary causes affecting body weight; * There is hypothyroidism at the time of screening that is not controlled with stable drug dosages; * Have a history of major surgery within 6 months prior to screening; * A history of drug abuse or alcohol dependence within the 6 months prior to screening; * History of malignant tumor within 5 years before screening; * Patients with other diseases that the researchers assessed would affect the safety of the subjects, affect the efficacy evaluation or compliance, or other conditions that the researchers considered unsuitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Affiliated Hospital of Jining Medical College

    Jining, Shandong, 272001, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, 563000, China

  • Anyang District Hospitai

    Anyang, Henan, 455000, China

  • Binzhou medical college affiliated hospital

    Binzhou, Shandong, 256603, China

  • CangZhou Hospital of Integrated TCM-WM·HEBEI

    Cangzhou, Hebei, 061012, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, 061012, China

  • FIRST HOSPITAL OF SHANXI Medical

    Taiyuan, Shanxi, 30012, China

  • First Affiliated Hospital Of Gannan Medical University

    Ganzhou, Jiangxi, 341000, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, 350001, China

  • Fuling Hospital affiliated to Chongqing University

    Chongqing, Chongqing Municipality, 408107, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, 730700, China

  • Genertec Liaoyou Gem Flower Hospiital

    Panjin, Liaoning, 124000, China

  • Handan First Hospital

    Handan, Hebei, 056000, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, 065000, China

  • Hefei Third People's Hospital

    Hefei, Anhui, 230000, China

  • Heilongjiang provincial hospital

    Haerbin, Heilongjiang, 150036, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, 046000, China

  • Huzhou Center Hostipal

    Huzhou, Zhejiang, 313000, China

  • Jiangyin Hospital of Traditional Chinese Medicine

    Wuxi, Jiangsu, 214499, China

  • Jiangyin People' Hospital

    Wuxi, Jiangsu, 214411, China

  • Jiaxing Second Hospital

    Jiaxing, Zhejiang, 314000, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, 730700, China

  • Liuzhou People'S Hospital

    Liuzhou, Guangxi, 545000, China

  • Loudi Central Hospital

    Loudi, Hunan, 417000, China

  • Luoyang Third People'S Hospital

    Luoyang, Henan, 471002, China

  • Mengchao Hepatobiliary Hospital Of Fujian Medical University

    Fuzhou, Fujian, 350001, China

  • Nanxishan Hospital of Guangxi Zhuang Autonomous Region

    Guilin, Guangxi, 541000, China

  • People'S Hospital of Zhengzhou

    Zhengzhou, Henan, 451100, China

  • Ruian People's Hospital

    Wenzhou, Zhejiang, 325200, China

  • Shanghai Jiading Central Hospital

    Shanghai, Shanghai Municipality, 201800, China

  • Shanghai Pudong New Area People's Hospital

    Shanghai, Shanghai Municipality, 201299, China

  • Shanxi Provincial People's Hospital

    Xi'an, Shaanxi, 710068, China

  • Suining Central Hospital

    Suining, Sichuan, 629000, China

  • Tangshan GongRen Hospital

    Tangshan, Hebei, 63000, China

  • The Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, 067000, China

  • The Affiliated Hospital of Southwet Medical University

    Luzhou, Sichuan, 646000, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400010, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350001, China

  • The First Affiliated Hospital of Shihezi University

    Shihezi, Xinjiang, 832008, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130000, China

  • The First People's Hospital of Xiaoshan District

    Hangzhou, Zhejiang, 311200, China

  • The First affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, 473007, China

  • The Fourth Hospital of Changsha

    Changsha, Hunan, 410023, China

  • The Second Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, 830000, China

  • The Second Affiliated Hospital of Zhengzhou Univerisity

    Zhengzhou, Henan, 450014, China

  • The Second Hospital Of Hebei Medical University

    Shijiazhuang, Hebei, 050061, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, 130000, China

  • The Second People Hospital of Lianyungang

    Lianyungang, Jiangsu, 222000, China

  • The Second People's Hospital of Yibin City

    Yibin, Sichuan, 644000, China

  • The Southwest Hospital of Amu

    Chongqing, Chongqing Municipality, 400038, China

  • The Third Affiliated Hospital of Qiqihar Medical College

    Qiqihar, Heilongjiang, 161000, China

  • The first Affiliated Hospital of GUANGXI medical university

    Nanning, Guangxi, 530021, China

  • The sixth people's hospital at of Shenyang

    Shenyang, Liaoning, 110006, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, 214023, China

  • Wuzhou GongRen Hospital

    Wuzhou, Guangxi, 543001, China

  • Xi'An International Medical Center Hospital

    Xi'an, Shaanxi, 710100, China

  • Xinyu People's Hospital

    Xinyu, Jiangxi, 338000, China

  • XuZhou Cancer Hospital

    Xuzhou, Jiangsu, 221018, China

  • XuZhou Central Hospital

    Xuzhou, Jiangsu, 221018, China

  • Xuancheng People'S Hospital

    Xuancheng, Anhui, 242000, China

  • Yichang Central People's Hospital

    Yichang, Hubei, 443008, China

  • Yichang Central People's Hospital

    Yichang, Hubei, 443100, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 434000, China

  • Zibo Central Hospital

    Zibo, Shandong, 255020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.